Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cambium BioASX:CMB +11.11%26 Days Sales Outstanding is 0.00 as of Dec. 2025. GuruFocus rates ASX:CMB with a GF Score™ of 26/100. The stock has 4 warning signs investors should review. Among 839 Biotechnology companies, Cambium Bio ranks worse than 119189.39% on this metric.
The historical rank and industry rank for Cambium Bio's Days Sales Outstanding or its related term are showing as below:
During the past 12 years, Cambium Bio's highest Days Sales Outstanding was 93805.00. The lowest was 93805.00. And the median was 93805.00.
ASX:CMB's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 69.33 * Ranked among companies with meaningful Days Sales Outstanding only.
Cambium Bio's Days Sales Outstanding
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
Cambium Bio (ASX:CMB) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Cambium Bio Days Sales Outstanding Related Terms
Cambium Bio Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Cambium Bio's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CMB vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Cambium Bio's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambium Bio Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cambium Bio's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Cambium Bio's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cambium Bio (ASX:CMB) has a Days Sales Outstanding of 0.00 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Cambium Bio and its competitors. Over the past decade, Cambium Bio's Days Sales Outstanding has ranged from 93,805.00 to 93,805.00. According to the industry distribution chart, Cambium Bio ranks #999999 out of 839 companies in the Biotechnology industry.
Is Cambium Bio's Days Sales Outstanding too high?
Cambium Bio's current Days Sales Outstanding is 0.00. Over the past 10 years, this metric has ranged from a low of 93,805.00 to a high of 93,805.00. Based on the distribution chart, Cambium Bio ranks #999999 out of 839 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cambium Bio has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cambium Bio ranks #999999 out of 839 companies for Days Sales Outstanding. This places Cambium Bio in the lower half of its industry. The industry median Days Sales Outstanding is 69.33. Historically, Cambium Bio's own Days Sales Outstanding has ranged from 93,805.00 to 93,805.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 69.33, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Cambium Bio and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 69.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambium Bio's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current Days Sales Outstanding of 0.00. The current Days Sales Outstanding is 0.00. Cambium Bio's overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current Days Sales Outstanding is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
26GF Score
Get the complete analysis for ASX:CMB
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMB has been successfully added to your 
